+ND Capital Fund (f.k.a. NanoDimension)

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates,

Selecta Biosciences is a biopharmaceutical company that develops immunotherapies and vaccines for the treatment and prevention of human diseases, focusing on autoimmune diseases and gene therapies.

Serotiny is a therapeutic discovery company that designs new genes for next generation cell & gene therapies. We invent therapeutic multi-domain proteins in high-throughput by orchestrating software, mammalian synthetic biology, and therapeutic expertise. At the heart of Serotiny’s technology is a discovery platform involving the close interworking of computationally aided protein design, high-throughput cellular assays, and sophisticated data-driven analytics.

SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer what we believe can be a broad range of potential therapeutics.

Arc Therapeutics is a stealth-stage biopharmaceutical company advancing differentiated medicines for CNS patient populations with high unmet medical needs. They also partner with hospitals to provide a radiosurgical solution dedicated to the management of metastatic brain tumors.

Emulate leverages human biology and technology to create Organ-Chips, which are advanced models for drug development and safety testing, aiming to replace animal testing with human-relevant alternatives.

Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of cancer and autoimmune diseases. Their investigational allogeneic T-cell immunotherapies harness the power of regulatory T cells to provide better outcomes with fewer risks for patients.

Octant is a therapeutics company building small molecule drugs that modulate cellular mechanisms. They focus on next-generation drug discovery using synthetic biology, high throughput chemistry, and AI/ML to target complex diseases, particularly those caused by protein misfolding.

Visby Medical develops portable PCR testing technology for rapid infectious disease diagnosis, including a rapid Flu-COVID test designed for at-home use.

Nutcracker Therapeutics, Inc. is a biotechnology CRDMO company that combines advanced engineering with high-precision biosynthesis to unlock the promise of RNA. The company’s mission is to drive forward the development of safe and effective RNA-based personalized therapeutics through its complete technology platform, which encompasses the design, delivery, and manufacturing of RNA molecules.

Partillion Bioscience offers a unique platform for functional single-cell biology research, utilizing their patented Nanovial technology to capture and analyze secreted molecules from individual cells in a high-throughput manner.

AIRNA is committed to delivering the promise of RNA editing to people with rare diseases and common conditions, developing novel medicines with the potential to deliver functional cures for patients.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Invests in early-stage life sciences companies, often backing founders when they are no more than an idea.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.